How should I evaluate, diagnose, and manage cyclical vomiting syndrome in a patient with recurrent stereotyped episodes of intense nausea and vomiting separated by symptom‑free intervals?

Cyclic Vomiting Syndrome: Evaluation, Diagnosis, and Management

Diagnostic Approach

Diagnose CVS clinically using Rome IV criteria: stereotypical episodes of acute-onset vomiting lasting <7 days, ≥3 discrete episodes in the past year (with ≥2 in the prior 6 months), separated by ≥1 week of baseline health, and no vomiting between episodes. 1

Key Clinical Features to Identify

• Stereotyped pattern is essential—each patient exhibits identical timing, duration, and symptom clusters that repeat with every episode. 2, 1
• Prodromal symptoms occur in ~65% of patients, manifesting as impending sense of doom, panic, anxiety, diaphoresis, mental fog, restlessness, headache, bowel urgency, or flushing, typically lasting a median of 1 hour before vomiting begins. 2, 1
• Episodes most commonly begin in early morning hours (pre-dawn). 2
• Abdominal pain is present in most CVS patients and should never be used to exclude the diagnosis. 2, 1
• Personal or family history of migraine is present in 20-30% of CVS patients and supports the diagnosis. 2, 1

Initial Laboratory Evaluation

• Obtain complete blood count, serum electrolytes and glucose, liver function tests, serum lipase, urinalysis, and urine drug screen to assess for cannabis use. 2, 1
• Obtain baseline ECG before starting prophylactic therapy due to QTc prolongation risk with amitriptyline. 2
• Pregnancy testing in women of childbearing age. 2

Critical Diagnostic Distinction: CVS vs. Cannabinoid Hyperemesis Syndrome

Screen all patients for cannabis use ≥4 times weekly for >1 year before confirming CVS diagnosis—this pattern suggests cannabinoid hyperemesis syndrome (CHS) rather than CVS and requires 6 months of cannabis cessation to differentiate. 2, 1

• Hot-water bathing occurs in 71% of CHS patients but also in 48% of CVS patients without cannabis exposure, so this behavior alone does not distinguish between the two conditions. 2, 3
• If cannabis use criteria are met, change the working diagnosis from CVS to CHS; definitive treatment requires cannabis cessation. 2

Psychiatric Comorbidity Screening

• Screen all patients for anxiety, depression, and panic disorder—these are present in 50-60% of CVS patients, and treating underlying anxiety decreases CVS episode frequency. 2, 1, 3

---

Disease Severity Classification

Classify CVS severity to determine treatment intensity: 2, 3

• Mild CVS: <4 episodes/year, each lasting <2 days, no ED visits or hospitalizations → requires abortive therapy only. 2, 3
• Moderate-severe CVS: ≥4 episodes/year, lasting >2 days, requiring ≥1 ED visit or hospitalization → requires both prophylactic and abortive therapy. 2, 3

---

Management Strategy

Prophylactic Therapy (for Moderate-Severe CVS)

Start amitriptyline 25 mg at bedtime as first-line prophylaxis, titrating by 10-25 mg every 2 weeks to a target of 75-150 mg nightly (or 1-1.5 mg/kg). 2

• Slow titration optimizes efficacy while limiting side effects (dry mouth, blurred vision, constipation, weight gain, daytime sedation). 2
• Administer at night to reduce daytime sedation and anticholinergic effects. 2
• Response rate is 67-75% in clinical studies. 2, 3
• Monitor baseline ECG for QTc prolongation risk before initiating therapy. 2

Second-line prophylactic options (if amitriptyline fails or is not tolerated): 2

• Topiramate: Start 25 mg daily, titrate to 100-150 mg daily in divided doses; monitor electrolytes and renal function twice yearly. 2
• Levetiracetam: Start 500 mg twice daily, titrate to 1000-2000 mg daily in divided doses; monitor CBC. 2
• Zonisamide: Start 100 mg daily, titrate to 200-400 mg daily; monitor electrolytes and renal function twice yearly. 2

Abortive Therapy (Prodromal Phase)

Educate patients to recognize their stereotypical prodromal symptoms and administer abortive medications immediately—the probability of aborting an episode is highest when medications are taken at prodrome onset. 2, 3

Standard abortive regimen: 2

• Sumatriptan 20 mg intranasal spray (can repeat once after 2 hours, maximum 2 doses per 24 hours) administered in head-forward position to optimize nasal receptor contact. 2
• Ondansetron 8 mg sublingual every 4-6 hours during the episode. 2

Additional abortive agents: 2, 3

• Promethazine 12.5-25 mg oral/rectal every 4-6 hours. 2
• Prochlorperazine 5-10 mg every 6-8 hours or 25 mg suppository every 12 hours. 2
• Sedatives (alprazolam, lorazepam, diphenhydramine) to truncate the episode—use caution in adolescents with substance abuse risk. 2

Emergency Department Management (Emetic Phase)

If home abortive therapy fails, immediate ED interventions include: 2, 3

• Place patient in a quiet, dark room to minimize sensory stimulation, as patients in the emetic phase are often agitated and have difficulty communicating. 2, 3
• Aggressive IV fluid replacement with dextrose-containing fluids for rehydration and metabolic support. 2, 3
• Ondansetron 8 mg IV every 4-6 hours as first-line antiemetic. 2
• IV ketorolac 15-30 mg every 6 hours (maximum 5 days, daily maximum 120 mg) as first-line non-narcotic analgesia—avoid opioids as they worsen nausea and carry addiction risk. 2, 3
• IV benzodiazepines for sedation. 2, 3
• Droperidol or haloperidol for refractory cases. 2, 3
• Check and correct electrolyte abnormalities immediately. 3

---

Lifestyle Modifications and Trigger Management

All patients require: 2

• Regular sleep schedule, avoiding sleep deprivation. 2
• Avoiding prolonged fasting. 2
• Stress management techniques—stress is a trigger in 70-80% of CVS patients (including positive stressors such as birthdays and vacations). 2
• Identifying and avoiding individual triggers (hormonal fluctuations, travel, motion sickness, acute infections, surgery, intense exercise). 2

---

Common Pitfalls to Avoid

• Missing the prodromal window dramatically reduces abortive therapy effectiveness—patient education to recognize and act on prodrome is critical. 2, 3
• Do not dismiss abdominal pain as an exclusion criterion—it is present in most CVS attacks. 2, 1
• Do not misinterpret self-soothing behaviors (excessive water intake, self-induced vomiting) as malingering—these are characteristic coping mechanisms in CVS. 2, 3
• Do not overlook retching and nausea—these symptoms are equally disabling as vomiting itself and require aggressive treatment. 2, 3
• Do not underestimate severity—approximately one-third of adults with CVS become disabled. 2, 1, 3

---

Special Populations

Coalescent CVS

• A distinct subgroup experiences progressively longer and more frequent episodes, eventually leading to daily nausea and vomiting with few asymptomatic days. 2
• Manage with prophylactic therapy comparable to moderate-severe CVS (amitriptyline), acknowledging the heightened therapeutic challenge. 2